Toggle Main Menu Toggle Search

Open Access padlockePrints

The Newcastle University research output collection, currently available on ePrints, will shortly be moving to a new open repository platform, Figshare. To prepare for the data migration we have paused adding new content to ePrints, and will resume once the new repository is launched. During this time you will continue to have access to ePrints (but no new content will appear). We will share updates here when available.

Efficacy of Platelet-Rich Plasma Versus Placebo for the Treatment of Greater Trochanteric Pain Syndrome A Double-Blinded Randomized Controlled Trial

Lookup NU author(s): Dr Ismael Atchia, Dr Richard Holleyman, Ajay MalviyaORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

© 2025 Lippincott Williams and Wilkins. All rights reserved.Background: Greater trochanteric pain syndrome (GTPS) is a painful condition that can impair a patient’s quality of life. If nonoperative measures fail, progressively more invasive treatment options may be required. This clinical trial aimed to evaluate the effectiveness of ultrasound-guided leukocyte-rich platelet-rich plasma (LR-PRP) injections in the treatment of refractory GTPS caused by bursitis and/or gluteal tendinopathy. Methods: An ethically approved, adequately powered, double-blinded randomized controlled trial (RCT) was conducted to evaluate the clinical outcomes in randomized LR-PRP and placebo groups using the International Hip Outcome Tool-12 (iHOT-12), a visual analogue scale (VAS) for pain, the modified Harris hip score (mHHS), the EuroQol 5-Dimensions (EQ-5D) questionnaire, and the presence or absence of complications. All injections were performed under ultrasound guidance into the trochanteric bursa and gluteus medius tendon. Results: The final analysis included 79 patients (39 in the LR-PRP and 40 in the placebo group; 73 female and 6 male; all Caucasian). Both the LR-PRP and the placebo group generally had improvement from baseline that was maintained to 12 months. The only deterioration in scores compared to baseline was seen in the LR-PRP group for the iHOT-12 at 12 months, the EQ-5D index at 3 and 6 months, and the EQ-5D VAS at all follow-up time points. However, there was no significant difference between the 2 groups at any follow-up point (p > 0.05). A multivariable linear regression model, with adjustment for age, sex, body mass index, and preoperative baseline score, did not reveal any significant associations between iHOT-12 and EQ-5D score gains at 12 months and treatment. Conclusions: This randomized trial found no significant difference in outcomes between LR-PRP and placebo for the treatment of greater trochanteric pain up to 6 months following the intervention. As a result, we do not support the routine use of PRP for the treatment of this condition.

Publication metadata

Author(s): Atchia I, Ali M, Oderuth E, Holleyman R, Malviya A

Publication type: Article

Publication status: Published

Journal: Journal of Bone and Joint Surgery

Year: 2025

Volume: 107

Issue: 5

Pages: 444-451

Print publication date: 05/03/2025

Online publication date: 13/01/2025

Acceptance date: 02/04/2018

ISSN (print): 0021-9355

ISSN (electronic): 1535-1386

Publisher: Lippincott Williams and Wilkins

URL: https://doi.org/10.2106/JBJS.24.00763

DOI: 10.2106/JBJS.24.00763

Altmetrics

Altmetrics provided by Altmetric

Share